Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Innate Pharma SA reported its third quarter 2025 business update and financial results, highlighting progress in key programs, including FDA clearance for TELLOMAK-3 and advancements in lacutamab for Sézary syndrome. The company anticipates dose-escalation data from IPH4502 in early 2026 and results from the monalizumab PACIFIC-9 study later in 2026. Financially, Innate Pharma holds €6.1 million in cash and equivalents, and €10.4 million in non-current financial instruments. Further risk details are available in filings with the French Financial Markets Authority and the U.S. SEC.
Innate Pharma SA announced a business update and financial results for the first nine months of 2025. The company highlighted progress across its key programs, including receiving FDA clearance to initiate TELLOMAK-3 and advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval in Sézary syndrome. Dose-escalation data from IPH4502, a Nectin-4 antibody-drug conjugate, is expected in the first half of 2026, with results from the monalizumab PACIFIC-9 study anticipated in the second half of 2026. The company also reported its financial position, noting cash, cash equivalents, short-term investments (€6.1 million), and non-current financial instruments (€10.4 million). Further details on risks and uncertainties are available in the company’s filings with the French Financial Markets Authority and the U.S. Securities and Exchange Commission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
